Puma Biotechnology (Puma Biotechnology) Interest Expense : $-13.4 Mil (TTM As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Puma Biotechnology Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Puma Biotechnology's interest expense for the three months ended in Mar. 2024 was $ -3.4 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-13.4 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Puma Biotechnology's Operating Income for the three months ended in Mar. 2024 was $ -2.3 Mil. Puma Biotechnology's Interest Expense for the three months ended in Mar. 2024 was $ -3.4 Mil. Puma Biotechnology did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Puma Biotechnology Interest Expense Historical Data

The historical data trend for Puma Biotechnology's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Puma Biotechnology Interest Expense Chart

Puma Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-15.02

-14.05

-12.81

-11.59

-13.33

Puma Biotechnology Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-3.31	-3.33	-3.34	-3.35	-3.36

Puma Biotechnology Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.4 Mil.

Puma Biotechnology (NAS:PBYI) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Puma Biotechnology's Interest Expense for the three months ended in Mar. 2024 was $-3.4 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-2.3 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $60.4 Mil.

Puma Biotechnology's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Puma Biotechnology did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Puma Biotechnology (Puma Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Puma Biotechnology Inc (NAS:PBYI) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

10880 Wilshire Boulevard, Suite 2150, Los Angeles, CA, USA, 90024

Website

http://www.pumabiotechnology.com

Puma Biotechnology Inc is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The company in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. FDA in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the US as NERLYNX.

Executives

Alan H Auerbach	director, 10 percent owner, officer: PRESIDENT, CEO & SECRETARY	10940 WILSHIRE BLVD. SUITE 600, LOS ANGELES CA 90024
Alvin F Wong	officer: Chief Scientific Officer	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Maximo F Nougues	officer: Chief Financial Officer	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Jeffrey Jerome Ludwig	officer: Chief Commercial Officer	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Douglas M Hunt	officer: See Remarks	C/O PUMA BIOTECHNOLOGY,INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Michael Patrick Miller	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4 L2
Adrian Senderowicz	director	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Troy Edward Wilson	director	C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Allison Dorval	director	C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Brian M Stuglik	director	C/O VERASTEM, INC., 117, NEEDHAM MA 02494
Jay M Moyes	director
Alessandra Cesano	director	700 BALTIC CIRCLE, SUITE 716, REDWOOD CITY CA 94065
Ann Calby Miller	director	C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Richard Paul Bryce	officer: SR VP, CLINICAL RESEARCH & DEV	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Hugh O'dowd	director	C/O NEON THERAPEUTICS, INC., 40 ERRIE STREET SUITE 110, CAMBRIDGE MA 02139